Julie Gralow, Chief Medical Officer at American Society of Clinical Oncology, shared a post on LinkedIn by American Society of Clinical Oncology (ASCO), adding:
“Many older cancer drugs were approved using a maximum tolerated dose (MTD) strategy. But we’ve learned a lot since then!
It’s crucial to revisit the dosing of established therapies through dose optimization studies.
The ASCO CDK study is studying dose optimization in patients aged 65 and older with metastatic breast cancer.
Why?
- Better Side Effects: Lower, optimized doses can often mean fewer severe side effects without losing efficacy.
- Improved Adherence: A more tolerable regimen means patients can stick with their treatment longer.
- Enhanced Quality of Life: Less toxicity directly translates to a better quality of life for patients.
It’s not about fewer drugs, it’s about the right dose.
Let’s push for dose optimization for all cancer treatments to improve patient outcomes!”
Quoting American Society of Clinical Oncology (ASCO)‘s post:
“In this short video, Dr. Julie Gralow shares why finding the best dose of the drug for each patient is important.
Watch now and learn how you can get involved.”
Proceed to the video attached to the post.
More posts featuring Julie Gralow on OncoDaily.